Welcome to our dedicated page for Royalty Pharma plc news (Ticker: RPRX), a resource for investors and traders seeking the latest updates and insights on Royalty Pharma plc stock.
Royalty Pharma plc (Nasdaq: RPRX) is the leading acquirer of revenue-producing intellectual property, primarily focusing on royalty interests in marketed and late-stage biopharmaceutical products. Established in 1996, the company has built a robust portfolio with over $13 billion in assets and has invested nearly $5.8 billion to date. Royalty Pharma excels in acquiring and managing diverse royalty interests across various therapeutic areas, mitigating the common risks associated with biopharmaceutical investments.
Royalty Pharma's portfolio includes royalties on more than 35 commercial products, such as AbbVie and Johnson & Johnson's Imbruvica for blood cancers, Biogen's Tysabri for multiple sclerosis, and Vertex's cystic fibrosis drugs. The company also holds interests in 14 development-stage products, demonstrating its commitment to funding innovation in the biopharmaceutical sector.
Recent achievements include a $525 million acquisition of royalties and milestones on frexalimab, a promising therapy developed by Sanofi for multiple sclerosis and other immune-mediated diseases. This transaction enhances Royalty Pharma's development-stage portfolio, reinforcing its potential for long-term growth.
Financially, Royalty Pharma reported first-quarter 2024 results reflecting strong royalty receipts growth, driven by key therapies like Trelegy and Vertex’s cystic fibrosis franchise. The company maintains a solid liquidity position with $843 million in cash and cash equivalents and a total debt of $6.3 billion.
Royalty Pharma's strategic partnerships span a broad spectrum of innovators, from academic institutions and research hospitals to leading global pharmaceutical companies. This extensive collaboration network underscores the company's pivotal role in advancing medical research and providing essential funding for late-stage clinical trials and new product launches.
For more information, visit www.royaltypharma.com.
The board of directors of Royalty Pharma (Nasdaq: RPRX) has declared a dividend of $0.20 per Class A ordinary share for the second quarter of 2023. This dividend will be distributed on June 15, 2023, to shareholders recorded by the close of business on May 19, 2023. Founded in 1996, Royalty Pharma is the largest purchaser of biopharmaceutical royalties, collaborating across the industry to fund innovation. Its portfolio includes royalties from over 35 commercial products like Vertex’s Trikafta and AbbVie’s Imbruvica, among others. The company plays a pivotal role in funding both late-stage clinical trials and acquiring existing royalties, supporting advancements in biopharmaceuticals.
Royalty Pharma (Nasdaq: RPRX) has announced its plan to report first quarter 2023 financial results on May 9, 2023, before the U.S. markets open. A conference call, available via webcast, will be held at 8:00 a.m. ET on the same day.
The company, established in 1996, is recognized as the largest buyer of biopharmaceutical royalties, funding innovation across the industry. Royalty Pharma collaborates with various organizations, including academic institutions and pharmaceutical companies, and currently holds a portfolio of royalties on over 35 commercial products, which includes notable therapies such as Vertex’s Trikafta and Biogen’s Tysabri.
Royalty Pharma plc (Nasdaq: RPRX) has authorized a share repurchase program of up to $1.0 billion for its Class A ordinary shares, with shareholder approval valid through June 2027. CEO Pablo Legorreta also plans to purchase an additional $50 million of these shares. This initiative reflects confidence in Royalty Pharma's growth potential and solid balance sheet, boosted by recent Biohaven-related payments. The company targets capital deployment of $10 to $12 billion over the next five years to invest in life sciences innovation while creating shareholder value.
Royalty Pharma has acquired an interest in PureTech’s royalty from Karuna Therapeutics for its therapy, KarXT, valued at up to
FAQ
What is the current stock price of Royalty Pharma plc (RPRX)?
What is the market cap of Royalty Pharma plc (RPRX)?
What does Royalty Pharma do?
What are some key products in Royalty Pharma’s portfolio?
How does Royalty Pharma fund innovation?
What is the company's financial position?
What recent acquisitions has Royalty Pharma made?
How does Royalty Pharma mitigate risks?
Who are Royalty Pharma’s partners?
What are Royalty Pharma’s recent financial results?
What is Royalty Pharma’s strategy?
Where can I find more information about Royalty Pharma?
